Intellia Therapeutics Names Brian Goff to its Board of Directors
June 14 2024 - 7:30AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage
gene editing company focused on revolutionizing medicine with
CRISPR-based therapies, today announced the appointment of Brian
Goff to its board of directors.
“We are very pleased to welcome Brian to our board of directors.
Brian’s extensive global commercialization experience, coupled with
his track record of success leading rare disease product launches,
will be invaluable to Intellia as we commercialize our first
CRISPR-based gene editing therapies for people with
life-threatening diseases,” said Intellia President and Chief
Executive Officer John Leonard, M.D. “We look forward to leveraging
Brian’s first-hand experience to guide us through the exciting
evolution from late-stage clinical development to a commercial
organization as we continue to lead a new era in medicine.”
Mr. Goff joins the Intellia board of directors with over three
decades of commercialization, operations and sales and marketing
experience at leading biopharmaceutical companies. He is a seasoned
and accomplished executive global leader focused on rare diseases.
Since 2022, he has been the chief executive officer of Agios
Pharmaceuticals and a member of its board of directors. He
previously served as executive vice president, chief commercial and
global operations officer of Alexion Pharmaceuticals until its
acquisition by AstraZeneca in 2021. Prior to Alexion, Mr. Goff was
chief operating officer and a member of the board of directors of
Neurovance until its acquisition by Otuska Pharmaceuticals. Before
joining Neurovance, Mr. Goff served as executive vice president and
president of the Hematology Division at Baxalta until its
acquisition by Shire. He previously served with Baxter Healthcare
Corporation as global hemophilia franchise head. Earlier in his
career, Mr. Goff held positions of increasing seniority in sales
and marketing with Novartis Pharmaceuticals and the pharmaceutical
division of Johnson & Johnson. Mr. Goff holds a bachelor’s
degree from Skidmore College and a Master of Business
Administration from the Wharton School at the University of
Pennsylvania.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading
clinical-stage gene editing company focused on revolutionizing
medicine with CRISPR-based therapies. The company’s in
vivo programs use CRISPR to enable precise editing of
disease-causing genes directly inside the human body.
Intellia’s ex vivo programs use CRISPR to engineer human
cells outside the body for the treatment of cancer and autoimmune
diseases. Intellia’s deep scientific, technical and clinical
development experience, along with its people, is helping set the
standard for a new class of medicine. To harness the full potential
of gene editing, Intellia continues to expand the capabilities of
its CRISPR-based platform with novel editing and delivery
technologies. Learn more at intelliatx.com and follow us
@intelliatx.
Forward-Looking Statements
This press release contains “forward-looking statements”
of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”)
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include, but are not
limited to, express or implied statements regarding Intellia’s
beliefs and expectations regarding the safety, efficacy and
advancement of our clinical programs and the anticipated
contribution of the members of our board of directors, specifically
Brian Goff, and our executives to our operations and progress.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: the risk
that any one or more of our product candidates, including those
that are co-developed, will not be successfully developed and
commercialized, including risks related to the authorization,
initiation and conduct of studies and other development
requirements for our product candidates such as advancing
CRISPR-based therapies into late-stage clinical development; the
risk that the results of preclinical studies or clinical studies
will not be predictive of future results in connection with future
studies; risks related to our relationship with third parties,
including our licensors, licensees and other collaborators; and
risks related to our, and our licensors’, ability to protect and
maintain our intellectual property position. For a discussion of
these and other risks and uncertainties, and other important
factors, any of which could cause Intellia’s actual results to
differ from those contained in the forward-looking statements, see
the section entitled “Risk Factors” in Intellia’s most recent
annual report on Form 10-K and quarterly report on Form 10-Q, as
well as discussions of potential risks, uncertainties, and other
important factors in Intellia’s other filings with the Securities
and Exchange Commission. All information in this press release is
as of the date of the release, and Intellia undertakes no duty to
update this information unless required by law.
Intellia Contacts:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communicationsian.karp@intelliatx.com
Lina LiSenior Director, Investor Relations and Corporate
Communicationslina.li@intelliatx.com
Media:Matt CrensonTen Bridge
Communicationsmedia@intelliatx.com
mcrenson@tenbridgecommunications.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From May 2024 to Jun 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2023 to Jun 2024